EMA Authorised: ReFacto AF (moroctocog alfa) — Pfizer Europe MA EEIG

View source ↗

Summary

The European Medicines Agency authorised ReFacto AF (moroctocog alfa) for the treatment of Hemophilia A. Decision date: 03/03/2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Refacto AF (Factor VIII, recombinant)

Snippet

Status: Authorised. Therapeutic area: Hemophilia A. MAH: Pfizer Europe MA EEIG. Decision date: 03/03/2025